Metabolic Reprogramming of the Ovarian Cancer Microenvironment in the Development of Antiangiogenic Resistance

Overview

Journal Acta Biochim Biophys Sin (Shanghai)

Specialties Biochemistry
Biophysics

Date 2023 Apr 6

PMID 37021977

Authors

Huiran Yue

Xin Lu

Affiliations

Soon will be listed here.

Abstract

Antiangiogenic therapies, such as treatment with bevacizumab, display modest survival benefits in ovarian cancer (OC) patients. After a transient response, the upregulation of compensatory proangiogenic pathways and the adoption of alternative vascularization processes lead to the development of resistance. Considering the high mortality rate of OC, there is an urgent need to uncover the underlying mechanisms of antiangiogenic resistance for the development of novel and effective treatment strategies. Recent investigations have confirmed that metabolic reprogramming in the tumor microenvironment (TME) exerts an essential effect on tumor aggressiveness and angiogenesis. In this review, we provide an overview of the metabolic crosstalk between OC and the TME, highlighting the regulatory mechanisms underlying the development of antiangiogenic resistance. Metabolic interventions may interrupt this complex and dynamic interactive network, providing a promising therapeutic option to improve clinical outcome in OC patients.

Citing Articles

TCF3 as a multidimensional biomarker: oncogenicity, genomic alterations, and immune landscape in pan-cancer analysis.

Nie H, Yu Y, Zhou S, Xu Y, Chen X, Qin X Acta Biochim Biophys Sin (Shanghai). 2024; 57(2):195-208.

PMID: 39205642 PMC: 11868920. DOI: 10.3724/abbs.2024126.

Direct antitumor activity of bevacizumab: an overlooked mechanism?.

Wang Z, Li J, Guo J, Wei P Front Pharmacol. 2024; 15:1394878.

PMID: 38716237 PMC: 11075754. DOI: 10.3389/fphar.2024.1394878.

Exploring the underlying biology of cancer and potential therapeutic strategies: a special issue focused on mechanism-based studies.

Gao D, Ge G, Guest Editors Acta Biochim Biophys Sin (Shanghai). 2023; 55(6):891-892.

PMID: 37337636 PMC: 10326411. DOI: 10.3724/abbs.2023114.

References

Lin Y, Liang X, Zhang X, Ni Y, Zhou X, Zhao X . Metabolic cross-talk between ovarian cancer and the tumor microenvironment-providing potential targets for cancer therapy. Front Biosci (Landmark Ed). 2022; 27(4):139. DOI: 10.31083/j.fbl2704139. View

Zhang Q, Li Y, Miao C, Wang Y, Xu Y, Dong R . Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma. Cancer Lett. 2018; 432:144-155. DOI: 10.1016/j.canlet.2018.05.049. View

Yuan L, Sheng X, Willson A, Roque D, Stine J, Guo H . Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. Endocr Relat Cancer. 2015; 22(4):577-91. PMC: 4500469. DOI: 10.1530/ERC-15-0192. View

Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S . Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol. 2020; 10:221. PMC: 7056882. DOI: 10.3389/fonc.2020.00221. View

Kuroki L, Guntupalli S . Treatment of epithelial ovarian cancer. BMJ. 2020; 371:m3773. DOI: 10.1136/bmj.m3773. View

Liu X, Zuo X, Sun X, Tian X, Teng Y . Hexokinase 2 Promotes Cell Proliferation and Tumor Formation through the Wnt/β-catenin Pathway-mediated Cyclin D1/c-myc Upregulation in Epithelial Ovarian Cancer. J Cancer. 2022; 13(8):2559-2569. PMC: 9174861. DOI: 10.7150/jca.71894. View

Bauerschlag D, Maass N, Leonhardt P, Verburg F, Pecks U, Zeppernick F . Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. J Transl Med. 2015; 13:146. PMC: 4504229. DOI: 10.1186/s12967-015-0511-3. View

Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N . Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol. 2021; 11:719836. PMC: 8406857. DOI: 10.3389/fonc.2021.719836. View

Falkenberg K, Rohlenova K, Luo Y, Carmeliet P . The metabolic engine of endothelial cells. Nat Metab. 2020; 1(10):937-946. DOI: 10.1038/s42255-019-0117-9. View

10.

Sun C, Li X, Guo E, Li N, Zhou B, Lu H . MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. Oncogene. 2019; 39(8):1681-1695. PMC: 8290627. DOI: 10.1038/s41388-019-1090-1. View

11.

Schiffmann L, Bruns C, Schmidt T . Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. Front Oncol. 2022; 12:897927. PMC: 9162757. DOI: 10.3389/fonc.2022.897927. View

12.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

13.

Nicholson L, Smith P, Hiller L, Szlosarek P, Kimberley C, Sehouli J . Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer. 2009; 125(6):1454-63. DOI: 10.1002/ijc.24546. View

14.

Huang H, Vandekeere S, Kalucka J, Bierhansl L, Zecchin A, Bruning U . Role of glutamine and interlinked asparagine metabolism in vessel formation. EMBO J. 2017; 36(16):2334-2352. PMC: 5556263. DOI: 10.15252/embj.201695518. View

15.

Kuczynski E, Reynolds A . Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. 2019; 23(1):55-74. DOI: 10.1007/s10456-019-09698-6. View

16.

Brown J, Chan D, Shank J, Griffith K, Fan H, Szulawski R . Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020; 5(11). PMC: 7308054. DOI: 10.1172/jci.insight.133247. View

17.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

18.

Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q . Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019; 38(1):81. PMC: 6377760. DOI: 10.1186/s13046-019-1095-1. View

19.

Wright G, Maroulakou I, Eldridge J, Liby T, Sridharan V, Tsichlis P . VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB J. 2008; 22(9):3264-75. PMC: 2518259. DOI: 10.1096/fj.08-106468. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View